Big pharmas seal alliances with Chinese groups for $73.6 billion
Western pharmaceutical companies are looking to the Asian giant for their future blockbusters, thereby accelerating deals that could exceed $250 billion in 2026.
Western pharmaceutical companies are turning to Chinese counterparts for potential blockbuster drugs, driving deals that could exceed $250 billion by 2026. So far this year, major Western pharmaceutical companies have signed agreements with Chinese counterparts worth over $82.4 billion. China is offering Western biopharmaceutical companies hope of finding their next big sellers as their top treatments approach patent expiration.
ING estimates that China will account for nearly a third of all new molecules in global pharmaceutical development this year, up from 4% in 2014.
Written by urgent.news from Expansion ES's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
